Display Settings:

Format

Send to:

Choose Destination
    J Neurooncol. 2007 Nov;85(2):229-30. Epub 2007 May 26.

    Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

    Source

    Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia. nsinghal@mail.rah.sa.gov.au

    Abstract

    Temozolomide is an alkylating agent used frequently in the management of gliomas. Although temozolomide is generally safe, rarely it can cause life threatening complications. Here we report the cases of two patients who developed prolonged and severe pancytopenia after low dose continuous temozolomide concurrently with cranial radiotherapy. The pancytopenia lasted two to six months. Both the patients were young, treatment naïve, and had temozolomide treatment for only approximately four weeks.

    PMID:
    17530175
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk